1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,790 | 6,050 | 13:04 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:54 | Biocytogen verkündet klinischen Meilenstein: Erster Patient in Phase-1-Studie von IDEAYAs erstklassigem B7H3/PTK7-bispezifischen TOP1-ADC IDE034 behandelt | 259 | Business Wire | IDE034 ist ein B7H3/PTK7-bispezifisches TOP1 ADC, das darauf ausgelegt ist, Tumorzellen, die sowohl B7H3 als auch PTK7 exprimieren, bevorzugt anzugreifen. Es wird derzeit sowohl als Monotherapie... ► Artikel lesen | |
| Do | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT ON PRELIMINARY FINANCIAL DATA FOR THE YEAR 2025 | - | HKEx | ||
| 12.02. | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 12.02. | BIOCYTOGEN-B (02315): (1) POLL RESULTS OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING HELD ON FEBRUARY 12, 2026; (2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR; ... | - | HKEx | ||
| 29.01. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED ANNUAL RESULTS FOR THE YEAR 2025 | 3 | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.01. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR; AND NOTICE OF THE 2026 FIRST EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.01. | BIOCYTOGEN-B (02315): PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 26.01. | BIOCYTOGEN-B (02315): CLOSURE OF REGISTER OF MEMBERS OF H SHARES | 4 | HKEx | ||
| 12.01. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT EXPANDED COLLABORATION WITH ACEPODIA THROUGH OPTION-BASED EVALUATION FRAMEWORK FOR FIRST-IN-CLASS DUAL-PAYLOAD ... | 1 | HKEx | ||
| 09.01. | Biocytogen und Acepodia erweitern Kooperation durch optionsbasiertes Evaluierungsmodell für bispezifische und Dual-Payload-First-in-Class-ADC (BsAD2C) | 470 | Business Wire | Die erweiterte Zusammenarbeit knüpft an die jüngsten gemeinsamen Entwicklungsanstrengungen von Acepodia und Biocytogen zur Evaluierung ausgewählter bispezifischer Antikörper- und Dual-Payload-ADC-Programme... ► Artikel lesen | |
| 09.01. | Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C) | 311 | Business Wire | Expanded collaboration builds on Acepodia and Biocytogen's recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs
Biocytogen Pharmaceuticals (Beijing)... ► Artikel lesen | |
| 31.12.25 | BIOCYTOGEN-B (02315): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 31.12.25 | BIOCYTOGEN-B (02315): RESIGNATION OF NON-EXECUTIVE DIRECTOR | 2 | HKEx | ||
| 24.12.25 | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT INCLUSION IN THE STOCK LIST UNDER THE STOCK CONNECT | 2 | HKEx | ||
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen schließt Börsengang am STAR-Markt ab und wird zum ersten globalen Arzneimittelentwickler mit "H+A"-Status | 540 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315), ein globales Biotechnologieunternehmen, das innovative Arzneimittelforschung vorantreibt, gab heute seine... ► Artikel lesen | |
| 10.12.25 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 568 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing... ► Artikel lesen | |
| 10.12.25 | BIOCYTOGEN-B (02315): NEXT DAY DISCLOSURE RETURNS | 4 | HKEx | ||
| 10.12.25 | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.: Biocytogen Completes STAR Market IPO, Becoming the First "H+A" Global Drug Innovator | 593 | Business Wire | Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. ("Biocytogen," SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful... ► Artikel lesen |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,046 | +14,00 % | Medigene: Zurückziehung - 18.11.2025 | ||
| BIOFRONTERA | 2,570 | -4,10 % | PTA-Adhoc: Biofrontera AG: Erhöhung Prognose | DJ PTA-Adhoc: Biofrontera AG: Erhöhung Prognose
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Sonstiges
Biofrontera AG: Erhöhung Prognose
Leverkusen... ► Artikel lesen | |
| CLINUVEL | 6,020 | +0,17 % | Clinuvel Pharmaceuticals Limited H1 Profit Declines | ||
| EDITAS MEDICINE | 1,835 | -1,66 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| ASEP MEDICAL | 0,121 | +0,83 % | ASEP Medical Holdings Inc (2): Asep Medical appoints Heinzl as interim CEO | ||
| CELLECTAR BIOSCIENCES | 3,290 | -2,66 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies | FLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,650 | +0,73 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update | Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of... ► Artikel lesen | |
| CLEAN HARBORS | 248,00 | -0,08 % | Clean Harbors Stock Barely Moves Despite Q4 Earnings and Revenue Beat | ||
| LIR LIFE SCIENCES | 0,622 | +2,30 % | EQS-Media: First-Mover mit erheblichem Skalierungspotenzial: LIR Life Sciences setzt Innovations-Roadmap fort | EQS-Media / 06.02.2026 / 16:20 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9), LIR oder das Unternehmen, freut sich bekannt zu geben, dass es mit "Neuland Laboratories Limited"... ► Artikel lesen | |
| MESOBLAST | 1,400 | +4,48 % | Mesoblast meldet 35 Mio. Dollar Umsatz - beginnt jetzt die nächste Phase? | ||
| SPERO THERAPEUTICS | 1,900 | +3,15 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,740 | +3,50 % | CStone Secures MHRA Approval For Sugemalimab In Stage III NSCLC In UK | ||
| PROTALIX BIOTHERAPEUTICS | 2,480 | +0,81 % | Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio (pegunigalsidase alfa) in the EU | Committee
for
Medicinal
Products
for
Human
Use
(CHMP)
issues
a
positive
opinion following re-examination, which
will
be reviewed by
the... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 116,00 | +0,87 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations | Primary endpoint met with statistically significant improvement (mean change of +2.13; p Achieved statistical significance on pre-specified key secondary endpoint (p 95% of trial participants aged... ► Artikel lesen | |
| PURPLE BIOTECH | 0,440 | -11,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 27.02.2026 | Das Instrument UZ9 CA4577022078 INSPIRATION ENERGY CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 27.02.2026 und ex Kapitalmassnahme am 02.03.2026 The instrument UZ9 CA4577022078 INSPIRATION ENERGY... ► Artikel lesen |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,900 Euro und damit +4,80 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.